Charles River Laboratories Announces Fourth-Quarter and Full-Year 2021 Results

Rhea-AI Summary

Charles River Laboratories International, Inc. (NYSE: CRL) reported fourth-quarter revenue of $905.1 million, a 14.4% increase year-over-year, and full-year revenue of $3.54 billion. Fourth-quarter GAAP EPS was $2.67, a 5.0% decline, while non-GAAP EPS rose 4.2% to $2.49.

The company reaffirmed its 2022 guidance, anticipating low-teens revenue growth driven by robust client demand. Significant contributions came from the Manufacturing segment, with revenues rising 47.4% in Q4. Despite challenges including the RMS Japan divestiture, CRL's portfolio growth remains strong.

Positive

• Fourth-quarter revenue increased by 14.4% year-over-year to $905.1 million.
• Full-year revenue rose 21.1% to $3.54 billion.
• Non-GAAP EPS increased by 4.2% to $2.49 in Q4.
• Strong organic revenue growth of 10.5% in Q4, driven by the Manufacturing segment.
• Reaffirms 2022 guidance of low-teens revenue growth.

Negative

• GAAP EPS decreased by 5.0% to $2.67 in Q4.
• Fourth-quarter net income attributable to common shareholders fell by 3.9% to $137.6 million.
• Loss from venture capital investments impacted earnings per share negatively.

– Fourth-Quarter Revenue of $905.1 Million and Full-Year Revenue of $3.54 Billion –

– Fourth-Quarter GAAP Earnings per Share of $2.67 and Non-GAAP Earnings per Share of $2.49 –

– Full-Year GAAP Earnings per Share of $7.60 and Non-GAAP Earnings per Share of $10.32 –

– Reaffirms 2022 Guidance –

WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2021 and reaffirmed guidance for 2022. For the quarter, revenue was $905.1 million, an increase of 14.4% from $791.0 million in the fourth quarter of 2020.

Acquisitions contributed 5.9% to consolidated fourth-quarter revenue growth. The divestiture of the Research Models and Services operations in Japan (RMS Japan) in October 2021 reduced reported revenue growth by 1.4%. The impact of foreign currency translation reduced reported revenue growth by 0.6%. Excluding the effect of these items, organic revenue growth was 10.5%, driven by contributions from all three business segments, led by the Manufacturing segment. The comparison to the COVID-19-related impact in 2020 increased both the reported and organic revenue growth rates by 0.5% in the fourth quarter of 2021.

On a GAAP basis, fourth-quarter net income attributable to common shareholders was $137.6 million, a decrease of 3.9% from $143.2 million for the same period in 2020. Fourth quarter diluted earnings per share on a GAAP basis were $2.67, a decrease of 5.0% from $2.81 for the fourth quarter of 2020. The decreases in GAAP net income and earnings per share primarily reflected a loss from the Company’s venture capital and other strategic investments of $0.19 per share in the fourth quarter of 2021, compared to a gain of $1.01 per share for the same period in 2020. The decreases were partially offset by acquisition-related adjustments associated with contingent consideration and a gain on the sale of RMS Japan.

On a non-GAAP basis, net income was $128.4 million for the fourth quarter of 2021, an increase of 5.2% from $122.1 million for the same period in 2020. Fourth-quarter diluted earnings per share on a non-GAAP basis were $2.49, an increase of 4.2% from $2.39 per share for the fourth quarter of 2020. The increases in non-GAAP net income and earnings per share were primarily driven by higher revenue and operating income, partially offset by a higher tax rate and net interest expense.

James C. Foster, Chairman, President and Chief Executive Officer, said, “2021 was another exceptional year for Charles River, with robust revenue and earnings growth, significant operating margin expansion, and meaningful cash flow generation. This performance reflects the unprecedented demand that we are seeing across most of our businesses, as well as the breadth and scientific depth of our leading, non-clinical portfolio.

“We believe that Charles River is a stronger company today than it has ever been. We have built the leading safety assessment franchise in the world; established an integrated, end-to-end discovery offering for both small and large molecules; and most recently, a comprehensive, scientifically advanced solution for our clients’ complex biologics and cell and gene therapies. We believe that the strength of our portfolio, coupled with robust industry fundamentals and the investments that we are making to accommodate client demand, will fuel low-teens revenue growth in 2022 and enable us to achieve our strategic and financial goals,” Mr. Foster concluded.

Fourth-Quarter Segment Results

Research Models and Services (RMS)

Revenue for the RMS segment was $165.6 million in the fourth quarter of 2021, an increase of 5.7% from $156.7 million in the fourth quarter of 2020. The impact of the RMS Japan divestiture reduced revenue by 7.2%, and the impact of foreign currency translation reduced revenue by 0.4%. Organic revenue growth of 13.3% was primarily driven by robust demand for research models, particularly in China, as well as higher revenue for research model services. Fourth quarter revenue for the cell supply business, which consists of HemaCare and Cellero, continued to be impacted by donor access and availability. The comparison to the COVID-19-related impact in 2020 increased both the reported and organic revenue growth rates by 2.3% in the fourth quarter of 2021.

In the fourth quarter of 2021, the RMS segment’s GAAP operating margin increased to 24.3% from 21.9% in the fourth quarter of 2020, and on a non-GAAP basis, the operating margin increased to 26.9% from 25.1%. The GAAP and non-GAAP operating margin increases were driven primarily by operating leverage from higher research models sales volume.

Discovery and Safety Assessment (DSA)

Revenue for the DSA segment was $534.1 million in the fourth quarter of 2021, an increase of 7.9% from $495.0 million in the fourth quarter of 2020. The impact of foreign currency translation reduced revenue by 0.4%, and acquisitions contributed 1.6% to DSA revenue growth. Organic revenue growth of 6.7% was driven principally by the Safety Assessment business, with the Discovery Services business also contributing.

In the fourth quarter of 2021, the DSA segment’s GAAP operating margin decreased to 17.8% from 18.4% in the fourth quarter of 2020. The decrease was primarily due to acquisition-related adjustments associated with contingent consideration. On a non-GAAP basis, the operating margin was essentially unchanged at 23.1%, compared to 23.2% in the fourth quarter of 2020. The impact of foreign currency translation reduced the DSA operating margin by approximately 40 basis points.

Manufacturing Solutions (Manufacturing)

Revenue for the Manufacturing segment was $205.3 million in the fourth quarter of 2021, an increase of 47.4% from $139.3 million in the fourth quarter of 2020. The acquisitions of Cognate BioServices (Cognate) and Vigene Biosciences (Vigene) contributed 27.8% to Manufacturing revenue growth, while the impact of foreign currency translation reduced revenue by 1.6%. Organic revenue growth of 21.2% was driven primarily by robust demand across the Biologics Testing Solutions, Microbial Solutions, and Avian Vaccine businesses. The comparison to the COVID-19-related impact in 2020 increased the reported and organic revenue growth rates in the fourth quarter of 2021 by 1.1% and 0.9%, respectively.

In the fourth quarter of 2021, the Manufacturing segment’s GAAP operating margin increased to 44.6% from 35.3% in the fourth quarter of 2020, primarily due to acquisition-related adjustments associated with contingent consideration. The non-GAAP operating margin decreased to 35.7% from 37.3% in the fourth quarter of 2020, driven primarily by the addition of the Cognate and Vigene CDMO businesses.

Full-Year Results

For 2021, revenue increased by 21.1% to $3.54 billion from $2.92 billion in 2020. Organic revenue growth was 15.1%. The comparison to the COVID-19-related impact in 2020 increased the reported and organic revenue growth rates in 2021 by 2.9% and 2.8%, respectively.

On a GAAP basis, net income attributable to common shareholders was $391.0 million in 2021, an increase of 7.3% from $364.3 million in 2020. Diluted earnings per share on a GAAP basis in 2021 were $7.60, an increase of 5.6% from $7.20 in 2020. On a GAAP basis, the Company recorded a loss from venture capital and other strategic investments totaling $0.44 per share in 2021, compared to a gain of $1.51 in 2020.

On a non-GAAP basis, net income was $530.5 million in 2021, an increase of 28.9% from $411.5 million in 2020. Diluted earnings per share on a non-GAAP basis in 2021 were $10.32, an increase of 26.9% from $8.13 in 2020.

Research Models and Services (RMS)

For 2021, RMS revenue was $690.4 million, an increase of 20.9% from $571.2 million in 2020. Organic revenue growth increased 19.5%. The comparison to the COVID-19-related impact in 2020 increased the reported and organic revenue growth rates in 2021 by 10.1% and 9.8%, respectively.

On a GAAP basis, the RMS segment operating margin increased to 24.2% in 2021 from 18.0% in 2020. On a non-GAAP basis, the operating margin increased to 27.3% in 2021 from 22.0% in 2020.

Discovery and Safety Assessment (DSA)

For 2021, DSA revenue was $2.11 billion, an increase of 14.7% from $1.84 billion in 2020. Organic revenue growth was 12.2%. The comparison to the COVID-19-related impact in 2020 increased both the reported and organic revenue growth rates by 0.8% in 2021.

On a GAAP basis, the DSA segment operating margin increased to 19.3% in 2021 from 17.7% in 2020. On a non-GAAP basis, the operating margin increased to 23.7% in 2021 from 23.4% in 2020.

Manufacturing Solutions (Manufacturing)

For 2021, Manufacturing revenue was $742.5 million, an increase of 44.1% from $515.4 million in 2020. Organic revenue growth was 20.6%. The comparison to the COVID-19-related impact in 2020 increased the reported and organic revenue growth rates in 2021 by 2.5% and 2.1%, respectively.

On a GAAP basis, the Manufacturing segment operating margin decreased to 33.2% in 2021 from 35.2% in 2020. On a non-GAAP basis, the operating margin decreased to 34.2% in 2021 from 37.4% in 2020.

Reaffirms 2022 Guidance

The Company is reaffirming its 2022 financial guidance, which was originally provided on January 11, 2022. As previously mentioned, the Company expects to benefit from a continuation of the robust client demand that it experienced last year and price increases, which is expected to drive low-teens revenue growth in 2022. On a non-GAAP basis, earnings per share growth in 2022 is expected to be similar to revenue growth, as modest operating margin improvement will be largely offset by less favorable below-the-line items, including a higher tax rate.

The Company’s 2022 guidance for revenue growth, earnings per share, and cash flow is as follows:

2022 GUIDANCE
Revenue growth, reported	13.0% – 15.0%
Contribution from acquisitions/divestitures, net (1)	--
Impact of 53rd week in 2022	~(1.5%)
Unfavorable/(favorable) impact of foreign exchange	~1.0%
Revenue growth, organic (2)	12.5% – 14.5%
GAAP EPS estimate	$9.20 – $9.45
Acquisition-related amortization	$1.90 – $2.10
Acquisition and integration-related adjustments (3)	~$0.10
Other items (4)	~$0.10
Non-GAAP EPS estimate	$11.50 – $11.75
Cash flow from operating activities	~$810 million
Capital expenditures	~$360 million
Free cash flow	~$450 million

Footnotes to Guidance Table:

(1) The contribution from acquisitions/divestitures (net) reflects only those transactions that were completed in 2021. The partial-year revenue impact from acquisitions, principally Cognate BioServices, Retrogenix, and Vigene Biosciences, is expected to be offset by the impact from the divestitures of RMS Japan and CDMO Sweden.

(2) Organic revenue growth is defined as reported revenue growth adjusted for acquisitions, divestitures, the 53^rd week in 2022, and foreign currency translation.

(3) These adjustments are related to the evaluation and integration of acquisitions and divestitures, and primarily include transaction, advisory, and certain third-party integration costs, as well as certain costs associated with acquisition-related efficiency initiatives.

(4) These items primarily relate to charges of approximately $0.10 associated with U.S. and international tax legislation that necessitated changes to the Company’s international financing structure.

Webcast

Charles River has scheduled a live webcast on Wednesday, February 16, at 8:30 a.m. ET to discuss matters relating to this press release. To participate, please go to ir.criver.com and select the webcast link. You can also find the associated slide presentation and reconciliations of GAAP financial measures to non-GAAP financial measures on the website.

Citi’s 2022 Virtual Healthcare Conference Presentation

Charles River will virtually present at Citi’s 2022 Virtual Healthcare Conference, on Wednesday, February 23^rd, at 9:30 a.m. ET. Management will provide an overview of Charles River’s strategic focus and business developments.

A live webcast of the presentation will be available through a link that will be posted on ir.criver.com. A webcast replay will be accessible through the same website shortly after the presentation and will remain available for approximately two weeks.

Non-GAAP Reconciliations

The Company reports non-GAAP results in this press release, which exclude often-one-time charges and other items that are outside of normal operations. A reconciliation of GAAP to non-GAAP results is provided in the schedules at the end of this press release.

Use of Non-GAAP Financial Measures

This press release contains non-GAAP financial measures, such as non-GAAP earnings per diluted share, non-GAAP operating income, non-GAAP operating margin, non-GAAP net income, and non-GAAP free cash flow. Non-GAAP financial measures exclude, but are not limited to, exclude the amortization of intangible assets, and other charges related to our acquisitions and divestitures; expenses associated with evaluating and integrating acquisitions and divestitures, as well as fair value adjustments associated with contingent consideration; charges, gains, and losses attributable to businesses or properties we plan to close, consolidate, or divest; severance and other costs associated with our efficiency initiatives; the impact of the termination of the Company’s U.S. pension plan; the write-off of deferred financing costs and fees related to debt financing; third-party costs associated with the remediation of unauthorized access into our information systems detected in March 2019; investment gains or losses associated with our venture capital and other strategic equity investments; certain costs in our Microbial Solutions business related to environmental litigation; and adjustments related to the recognition of deferred tax assets expected to be utilized as a result of changes to the our international financing structure and the revaluation of deferred tax liabilities as a result of foreign tax legislation. This press release also refers to our revenue in both a GAAP and non-GAAP basis: “organic revenue growth,” which we define as reported revenue growth adjusted for foreign currency translation, acquisitions, divestitures, and the impact of the 53^rd week in 2022. We exclude these items from the non-GAAP financial measures because they are outside our normal operations. There are limitations in using non-GAAP financial measures, as they are not presented in accordance with generally accepted accounting principles, and may be different than non-GAAP financial measures used by other companies. In particular, we believe that the inclusion of supplementary non-GAAP financial measures in this press release helps investors to gain a meaningful understanding of our core operating results and future prospects without the effect of these often-one-time charges, and is consistent with how management measures and forecasts the Company's performance, especially when comparing such results to prior periods or forecasts. We believe that the financial impact of our acquisitions and divestitures (and in certain cases, the evaluation of such acquisitions and divestitures, whether or not ultimately consummated) is often large relative to our overall financial performance, which can adversely affect the comparability of our results on a period-to-period basis. In addition, certain activities and their underlying associated costs, such as business acquisitions, generally occur periodically but on an unpredictable basis. We calculate non-GAAP integration costs to include third-party integration costs incurred post-acquisition. Presenting revenue on an organic basis allows investors to measure our revenue growth exclusive of acquisitions, divestitures, and foreign currency exchange fluctuations more clearly. Non-GAAP results also allow investors to compare the Company’s operations against the financial results of other companies in the industry who similarly provide non-GAAP results. The non-GAAP financial measures included in this press release are not meant to be considered superior to or a substitute for results of operations presented in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations. Reconciliations of the non-GAAP financial measures used in this press release to the most directly comparable GAAP financial measures are set forth in this press release, and can also be found on the Company’s website at ir.criver.com.

Caution Concerning Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “intend,” “will,” “would,” “may,” “estimate,” “plan,” “outlook,” and “project,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements also include statements regarding the impact of the COVID-19 pandemic; the projected future financial performance of Charles River and our specific businesses; client demand, particularly the future demand for drug discovery and development products and services, including our expectations for future revenue trends; our expectations with respect to pricing of our products and services; our expectations with respect to future tax rates and the impact of such tax rates on our business; our expectations with respect to the impact of acquisitions and divestitures completed in 2020 and 2021 on the Company, our service offerings, client perception, strategic relationships, revenue, revenue growth rates, and earnings; the development and performance of our services and products, including our investments in our portfolio; market and industry conditions including the outsourcing of services and spending trends by our clients; and Charles River’s future performance as delineated in our forward-looking guidance, and particularly our expectations with respect to revenue, the impact of foreign exchange, enhanced efficiency initiatives, and the assumptions surrounding the COVID-19 pandemic that form the basis for our annual guidance. Forward-looking statements are based on Charles River’s current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to: the COVID-19 pandemic, its duration, its impact on our business, results of operations, financial condition, liquidity, business practices, operations, suppliers, third party service providers, clients, employees, industry, ability to meet future performance obligations, ability to efficiently implement advisable safety precautions, and internal controls over financial reporting; the COVID-19 pandemic’s impact on client demand, the global economy and financial markets; the ability to successfully integrate businesses we acquire (including Cognate BioServices and Vigene Biosciences, and risks and uncertainties associated with Cognate’s and Vigene’s products and services, which are in areas that the Company did not previously operate); the timing and magnitude of our share repurchases; negative trends in research and development spending, negative trends in the level of outsourced services, or other cost reduction actions by our clients; the ability to convert backlog to revenue; special interest groups; contaminations; industry trends; new displacement technologies; USDA and FDA regulations; changes in law; continued availability of products and supplies; loss of key personnel; interest rate and foreign currency exchange rate fluctuations; changes in tax regulation and laws; changes in generally accepted accounting principles; and any changes in business, political, or economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 17, 2021 and the Quarterly Report on Form 10-Q as filed on November 3, 2021, as well as other filings we make with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this press release except as required by law.

Assessment of COVID-19 Impact in 2020

In this press release, the Company has provided its assessment for the impact from the COVID-19 pandemic in 2020, including on the Company's revenue. This assessment was determined using methodologies, assumptions, and estimates that vary depending on the specific reporting segment and situation. For the Research Models and Services segment, the assessment was primarily based on comparisons to daily historical research model sales volumes prior to the COVID-19 pandemic and the subsequent reduction in research model order activity associated with our clients’ COVID-19 pandemic-related site closures and/or their reduced on-site activity, as well as our discussions with clients, particularly of our research model services and HemaCare businesses, with regard to revenue expectations and operational impacts from the COVID-19 pandemic. For the Discovery and Safety Assessment segment, the assessment was based on multiple factors including, but not limited to, discussions with clients with regard to the cause of delays to discovery projects and safety assessment studies, location-specific actions to ensure employee safety in our facilities, the impact of remote versus in-person activities and services, and supply chain delays and other resource constraints. For the Manufacturing Solutions segment, the assessment was based on multiple factors including, but not limited to, analysis of the sales impact due to the COVID-19 pandemic, assessments of idle instruments and the related revenue streams due to the inability to access clients’ sites, as well as discussions with clients with regard to their revenue expectations and operations. The estimated revenue loss related to COVID-19 was also expected to be partially offset by incremental work on clients’ COVID-19 programs. Because this assessment involves risks and uncertainties, actual events and results may differ materially from these estimates and assumptions, and Charles River assumes no obligation and expressly disclaims any duty to update them.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
SCHEDULE 1
	CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(in thousands, except for per share data)
		Three Months Ended							Twelve Months Ended
		December 25, 2021				December 26, 2020			December 25, 2021			December 26, 2020
	Service revenue	$	709,819			$	618,229		$	2,755,579		$	2,296,156
	Product revenue		195,231				172,761			784,581			627,777
	Total revenue		905,050				790,990			3,540,160			2,923,933
	Costs and expenses:
	Cost of services provided (excluding amortization of intangible assets)		468,091				408,242			1,837,487			1,533,230
	Cost of products sold (excluding amortization of intangible assets)		89,847				82,780			368,035			317,162
	Selling, general and administrative		144,112				143,033			619,919			528,935
	Amortization of intangible assets		30,193				28,008			124,857			111,877
	Operating income		172,807				128,927			589,862			432,729
	Other income (expense):
	Interest income		309				63			652			834
	Interest expense		(11,546	)			(33,147	)		(73,910	)		(86,433	)
	Other income (expense), net		2,072				76,584			(35,894	)		99,984
	Income before income taxes		163,642				172,427			480,710			447,114
	Provision for income taxes		23,815				28,237			81,873			81,808
	Net income		139,827				144,190			398,837			365,306
	Less: Net income attributable to noncontrolling interests		2,249				999			7,855			1,002
	Net income attributable to common shareholders	$	137,578			$	143,191		$	390,982		$	364,304
	Earnings per common share
	Net income attributable to common shareholders:
	Basic	$	2.73			$	2.88		$	7.77		$	7.35
	Diluted	$	2.67			$	2.81		$	7.60		$	7.20
	Weighted-average number of common shares outstanding:
	Basic		50,471				49,754			50,293			49,550
	Diluted		51,555				51,028			51,425			50,611

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
SCHEDULE 2
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(in thousands, except per share amounts)
	December 25, 2021			December 26, 2020
Assets
Current assets:
Cash and cash equivalents	$	241,214		$	228,424
Trade receivables and contract assets, net of allowances for credit losses of $7,180 and $6,702, respectively		642,881			617,740
Inventories		199,146			185,695
Prepaid assets		93,543			96,712
Other current assets		97,311			72,560
Total current assets		1,274,095			1,201,131
Property, plant and equipment, net		1,291,068			1,124,358
Operating lease right-of-use assets, net		292,941			178,220
Goodwill		2,711,881			1,809,168
Client relationships, net		981,398			721,505
Other intangible assets, net		79,794			66,094
Deferred tax assets		40,226			37,729
Other assets		352,889			352,626
Total assets	$	7,024,292		$	5,490,831
Liabilities, Redeemable Noncontrolling Interests and Equity
Current liabilities:
Current portion of long-term debt and finance leases	$	2,795		$	50,214
Accounts payable		198,130			122,475
Accrued compensation		246,119			206,823
Deferred revenue		219,703			207,942
Accrued liabilities		228,797			149,820
Other current liabilities		137,641			102,477
Total current liabilities		1,033,185			839,751
Long-term debt, net and finance leases		2,663,564			1,929,571
Operating lease right-of-use liabilities		252,972			155,595
Deferred tax liabilities		239,720			217,031
Other long-term liabilities		242,859			205,215
Total liabilities		4,432,300			3,347,163
Redeemable noncontrolling interests		53,010			25,499
Equity:
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding		-			-
Common stock, $0.01 par value; 120,000 shares authorized; 50,480 shares issued and outstanding as of December 25, 2021 and 49,767 shares issued and outstanding as of December 26, 2020		505			498
Additional paid-in capital		1,718,304			1,627,564
Retained earnings		980,751			625,414
Treasury stock, at cost, 0 shares as of December 25, 2021 and December 26, 2020		-			-
Accumulated other comprehensive loss		(164,740	)		(138,874	)
Total equity attributable to common shareholders		2,534,820			2,114,602
Noncontrolling interest		4,162			3,567
Total equity		2,538,982			2,118,169
Total liabilities, redeemable noncontrolling interests and equity	$	7,024,292		$	5,490,831

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
SCHEDULE 3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(in thousands)
		Twelve Months Ended
		December 25, 2021			December 26, 2020
	Cash flows relating to operating activities
	Net income	$	398,837		$	365,306
	Adjustments to reconcile net income to net cash provided by operating activities:
	Depreciation and amortization		265,540			234,924
	Stock-based compensation		71,474			56,341
	Loss on debt extinguishment and other financing costs		29,964			3,661
	Deferred income taxes		(24,006	)		(133	)
	Loss (gain) on venture capital and strategic equity investments, net		30,420			(100,861	)
	Gain on sale of businesses		(25,026	)		-
	Contingent consideration		(34,303	)		(468	)
	Other, net		4,957			14,080
	Changes in assets and liabilities:
	Trade receivables and contract assets, net		(26,633	)		(85,627	)
	Inventories		(25,159	)		(18,379	)
	Accounts payable		44,901			748
	Accrued compensation		44,304			40,481
	Deferred revenue		(13,402	)		28,647
	Customer contract deposits		16,925			8,955
	Other assets and liabilities, net		2,006			(1,100	)
	Net cash provided by operating activities		760,799			546,575
	Cash flows relating to investing activities
	Acquisition of businesses and assets, net of cash acquired		(1,293,095	)		(418,628	)
	Capital expenditures		(228,772	)		(166,560	)
	Purchases of investments and contributions to venture capital investments		(45,555	)		(26,692	)
	Proceeds from sale of businesses, net		122,694			-
	Proceeds from sale of investments		6,532			11,401
	Other, net		264			(1,065	)
	Net cash used in investing activities		(1,437,932	)		(601,544	)
	Cash flows relating to financing activities
	Proceeds from long-term debt and revolving credit facility		6,951,113			2,230,988
	Proceeds from exercises of stock options		45,652			46,586
	Payments on long-term debt, revolving credit facility, and finance lease obligations		(6,242,877	)		(2,200,400	)
	Payment of debt extinguishment and financing costs		(38,255	)		-
	Purchase of treasury stock		(40,707	)		(23,979	)
	Other, net		(2,328	)		(5,947	)
	Net cash provided by financing activities		672,598			47,248
	Effect of exchange rate changes on cash, cash equivalents, and restricted cash		17,730			794
	Net change in cash, cash equivalents, and restricted cash		13,195			(6,927	)
	Cash, cash equivalents, and restricted cash, beginning of period		233,119			240,046
	Cash, cash equivalents, and restricted cash, end of period	$	246,314		$	233,119
	Supplemental cash flow information:
	Cash and cash equivalents	$	241,214		$	228,424
	Restricted cash included in Other current assets		4,023			3,074
	Restricted cash included in Other assets		1,077			1,621
	Cash, cash equivalents, and restricted cash, end of period	$	246,314		$	233,119
	Cash paid for income taxes	$	75,441		$	60,059
	Cash paid for interest	$	70,775		$	72,461
	Non-cash investing and financing activities:
	Purchases of Property, plant and equipment included in Accounts payable and Accrued liabilities	$	72,043		$	25,614
	Assets acquired under finance leases	$	1,567		$	1,571

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
SCHEDULE 4
RECONCILIATION OF GAAP TO NON-GAAP
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)(1)
(in thousands, except percentages)
		Three Months Ended							Twelve Months Ended
		December 25, 2021				December 26, 2020			December 25, 2021				December 26, 2020
Research Models and Services
	Revenue	$	165,575			$	156,697		$	690,437			$	571,152
	Operating income		40,188				34,381			166,814				102,706
	Operating income as a % of revenue		24.3	%			21.9	%		24.2	%			18.0	%
	Add back:
	Amortization related to acquisitions		4,075				3,975			20,104				19,556
	Severance		-				118			7				645
	Acquisition related adjustments (2)		359				876			1,576				2,375
	Site consolidation costs, impairments and other items		-				-			-				200
	Total non-GAAP adjustments to operating income	$	4,434			$	4,969		$	21,687			$	22,776
	Operating income, excluding non-GAAP adjustments	$	44,622			$	39,350		$	188,501			$	125,482
	Non-GAAP operating income as a % of revenue		26.9	%			25.1	%		27.3	%			22.0	%
	Depreciation and amortization	$	9,673			$	9,747		$	39,123			$	37,080
	Capital expenditures	$	31,667			$	13,902		$	61,188			$	29,487
Discovery and Safety Assessment
	Revenue	$	534,136			$	495,004		$	2,107,231			$	1,837,428
	Operating income		94,967				91,087			406,978				325,959
	Operating income as a % of revenue		17.8	%			18.4	%		19.3	%			17.7	%
	Add back:
	Amortization related to acquisitions		19,933				21,978			84,740				90,304
	Severance		(144	)			130			1,016				4,117
	Acquisition related adjustments (2)		8,016				828			4,374				3,673
	Site consolidation costs, impairments and other items		844				726			2,098				6,598
	Total non-GAAP adjustments to operating income	$	28,649			$	23,662		$	92,228			$	104,692
	Operating income, excluding non-GAAP adjustments	$	123,616			$	114,749		$	499,206			$	430,651
	Non-GAAP operating income as a % of revenue		23.1	%			23.2	%		23.7	%			23.4	%
	Depreciation and amortization	$	44,986			$	43,784		$	177,254			$	168,922
	Capital expenditures	$	40,694			$	59,217		$	101,477			$	105,653
Manufacturing Solutions
	Revenue	$	205,339			$	139,289		$	742,492			$	515,353
	Operating income		91,673				49,206			246,390				181,494
	Operating income as a % of revenue		44.6	%			35.3	%		33.2	%			35.2	%
	Add back:
	Amortization related to acquisitions		5,390				2,144			23,304				8,758
	Severance		1,278				428			3,622				2,413
	Acquisition related adjustments (2)		(25,281	)			-			(20,437	)			(421	)
	Site consolidation costs, impairments and other items (3)		217				151			1,331				320
	Total non-GAAP adjustments to operating income	$	(18,396	)		$	2,723		$	7,820			$	11,070
	Operating income, excluding non-GAAP adjustments	$	73,277			$	51,929		$	254,210			$	192,564
	Non-GAAP operating income as a % of revenue		35.7	%			37.3	%		34.2	%			37.4	%
	Depreciation and amortization	$	11,721			$	6,647		$	46,195			$	25,904
	Capital expenditures	$	24,869			$	12,302		$	58,877			$	26,287
Unallocated Corporate Overhead		$	(54,021	)		$	(45,747	)	$	(230,320	)		$	(177,430	)
	Add back:
	Severance		224				375			73				411
	Acquisition related adjustments (2)		1,343				4,020			30,354				13,996
	Other items (3)		39				-			39				(661	)
	Total non-GAAP adjustments to operating expense	$	1,606			$	4,395		$	30,466			$	13,746
	Unallocated corporate overhead, excluding non-GAAP adjustments	$	(52,415	)		$	(41,352	)	$	(199,854	)		$	(163,684	)
Total
	Revenue	$	905,050			$	790,990		$	3,540,160			$	2,923,933
	Operating income		172,807				128,927			589,862				432,729
	Operating income as a % of revenue		19.1	%			16.3	%		16.7	%			14.8	%
	Add back:
	Amortization related to acquisitions		29,398				28,097			128,148				118,618
	Severance		1,358				1,051			4,718				7,586
	Acquisition related adjustments (2)		(15,563	)			5,724			15,867				19,623
	Site consolidation costs, impairments and other items (3)		1,100				877			3,468				6,457
	Total non-GAAP adjustments to operating income	$	16,293			$	35,749		$	152,201			$	152,284
	Operating income, excluding non-GAAP adjustments	$	189,100			$	164,676		$	742,063			$	585,013
	Non-GAAP operating income as a % of revenue		20.9	%			20.8	%		21.0	%			20.0	%
	Depreciation and amortization	$	67,241			$	60,876		$	265,540			$	234,924
	Capital expenditures	$	98,775			$	87,854		$	228,772			$	166,560

(1)		Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.
(2)		These adjustments are related to the evaluation and integration of acquisitions, which primarily include transaction, third-party integration, and certain compensation costs, and fair value adjustments associated with contingent consideration.
(3)		Other items include certain costs in our Microbial Solutions business related to environmental litigation incurred during the three and twelve months ended December 25, 2021, which impacted Manufacturing Solutions; and third-party costs, net of insurance reimbursements, incurred during the twelve months ended December 26, 2020 associated with the remediation of the unauthorized access into the Company's information systems which was detected in March 2019, which impacted Unallocated Corporate Overhead.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
SCHEDULE 5
RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS (UNAUDITED)(1)
(in thousands, except per share data)
		Three Months Ended								Twelve Months Ended
		December 25, 2021				December 26, 2020				December 25, 2021				December 26, 2020
	Net income attributable to common shareholders	$	137,578			$	143,191			$	390,982			$	364,304
	Add back:
	Non-GAAP adjustments to operating income (Refer to previous schedule)		16,293				35,749				152,201				152,284
	Write-off of deferred financing costs and fees related to debt financing		-				-				26,089				-
	Venture capital and strategic equity investment losses (gains), net		13,142				(68,635	)			30,419				(100,861	)
	Gain due to sale of RMS Japan operations		(22,656	)			-				(22,656	)			-
	Loss due to U.S. Pension termination		-				10,283				-				10,283
	Other (2)		-				-				(2,942	)			-
	Tax effect of non-GAAP adjustments:
	Non-cash tax provision related to international financing structure (3)		1,028				1,454				4,809				4,444
	Enacted tax law changes		-				-				10,036				-
	Tax effect of the remaining non-GAAP adjustments		(16,936	)			87				(58,404	)			(18,953	)
	Net income attributable to common shareholders, excluding non-GAAP adjustments	$	128,449			$	122,129			$	530,534			$	411,501
	Weighted average shares outstanding - Basic		50,471				49,754				50,293				49,550
	Effect of dilutive securities:
	Stock options, restricted stock units and performance share units		1,084				1,274				1,132				1,061
	Weighted average shares outstanding - Diluted		51,555				51,028				51,425				50,611
	Earnings per share attributable to common shareholders:
	Basic	$	2.73			$	2.88			$	7.77			$	7.35
	Diluted	$	2.67			$	2.81			$	7.60			$	7.20
	Basic, excluding non-GAAP adjustments	$	2.55			$	2.45			$	10.55			$	8.30
	Diluted, excluding non-GAAP adjustments	$	2.49			$	2.39			$	10.32			$	8.13

(1)		Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.
(2)		Includes adjustments related to the gain on an immaterial divestiture and the finalization of the annuity purchase related to the termination of the Company's U.S. pension plan.
(3)		This adjustment relates to the recognition of deferred tax assets expected to be utilized as a result of changes to the Company's international financing structure.

	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
	SCHEDULE 6
	RECONCILIATION OF GAAP REVENUE GROWTH
	TO NON-GAAP REVENUE GROWTH, ORGANIC (UNAUDITED) (1)
	For the three months ended December 25, 2021		Total CRL	RMS Segment		DSA Segment		MS Segment
	Revenue growth, reported		14.4 %	5.7 %		7.9 %		47.4 %
	Decrease (increase) due to foreign exchange		0.6 %	0.4 %		0.4 %		1.6 %
	Contribution from acquisitions (2)		(5.9)%	- %		(1.6)%		(27.8)%
	Impact of divestitures (3)		1.4 %	7.2 %		- %		- %
	Non-GAAP revenue growth, organic (4)		10.5 %	13.3 %		6.7 %		21.2 %
	For the twelve months ended December 25, 2021		Total CRL	RMS Segment		DSA Segment		MS Segment
	Revenue growth, reported		21.1 %	20.9 %		14.7 %		44.1 %
	Decrease (increase) due to foreign exchange		(1.8)%	(2.2)%		(1.4)%		(2.2)%
	Contribution from acquisitions (2)		(4.6)%	(1.1)%		(1.1)%		(21.3)%
	Impact of divestitures (3)		0.4 %	1.9 %		- %		- %
	Non-GAAP revenue growth, organic (4)		15.1 %	19.5 %		12.2 %		20.6 %

(1)		Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.
(2)		The contribution from acquisitions reflects only completed acquisitions.
(3)		The Company sold both its RMS Japan operations and its gene therapy CDMO site in Sweden on October 12, 2021. This adjustment represents the revenue from these businesses for all applicable periods in 2021 and 2020.
(4)		Organic revenue growth is defined as reported revenue growth adjusted for acquisitions, divestitures and foreign exchange.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20220215006096/en/

Investor Contacts:

Todd Spencer

Corporate Vice President,

Investor Relations

781.222.6455

todd.spencer@crl.com

Media Contact:

Amy Cianciaruso

Corporate Vice President,

Chief Communications Officer

781.222.6168

amy.cianciaruso@crl.com

Source: Charles River Laboratories International, Inc.

FAQ

What were Charles River Laboratories' fourth-quarter earnings for 2021?

Charles River Laboratories reported fourth-quarter revenue of $905.1 million and GAAP earnings per share of $2.67.

What is the revenue growth rate for Charles River Laboratories in 2021?

Charles River Laboratories experienced a 21.1% increase in revenue for the full year 2021.

How did the divestiture of RMS Japan impact Charles River Laboratories' revenue?

The divestiture of RMS Japan reduced reported revenue growth by 1.4% in the fourth quarter.

What is the guidance for Charles River Laboratories in 2022?

Charles River Laboratories reaffirms its 2022 guidance, expecting low-teens revenue growth.

What factors contributed to the revenue growth of Charles River Laboratories' Manufacturing segment?

The Manufacturing segment's revenue increased by 47.4% in Q4, primarily due to acquisitions and robust demand.